Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide

Satoh, Jo; Takahashi, Kazuma; Takizawa, Yui; Ishihara, Hideharu; Hirai, Masashi; Katagiri, Hideki; Hinokio, Yoshinori; Suzuki, Susumu; Tsuji, Ichiro; Oka, Yoshitomo

doi:10.1016/j.diabres.2005.04.002

Cited by 44 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Third, secondary failure of sulfonylurea is an important issue at present. As reported by the ADOPT [12] and CHICAGO studies [17], long-term treatment of sulfonylurea may cause -cell dysfunction, resulting in aggravation of glycemic control [18,19]. In this study, glycemic control improved rapidly as shown by the results of glycoalbumin and HbA1c, which are comparable with those of the CHICAGO study.…”

Section: Discussionsupporting

confidence: 79%

Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes

Kanazawa¹,

Shimizu²,

Ebato³

et al. 2009

TODIAJ

View full text Add to dashboard Cite

Glimepiride is a potent sulfonylurea agent and is widely used for type 2 diabetic patients, however, the safety and efficacy of glimepiride in patients with fair diabetic control (HbA1c level: 6.5-7.9%) have not been investigated so far. Therefore, we investigated the safety and efficacy of glimepiride titration using self-monitoring blood glucose (SMBG) in the achievement of strict glycemic control in fairly controlled diabetic patients. Japanese type 2 diabetic patients who were diet-controlled or treated with alpha-glucosidase inhibitor or metformin, were randomly assigned into the SMBG group with titration of glimepiride using SMBG, or the conventional therapy group (control group) without SMBG. Glimepiride was initiated at a dose of 0.5 mg/day and plasma glucose, insulin, HbA1c, and glycoalbumin levels were evaluated for 6 months in both groups. The dose of glimepiride was titrated in the SMBG group according to the SMBG levels before breakfast and dinner. The mean dose of glimepiride at 6 months tended to be higher in the SMBG than the control group (1.0±0.8 vs 0.6±0.3mg/day), but not significant. At 6 months after glimepiride treatment, HbA1c levels were significantly lower than at baseline (SMBG: 7.2±0.5 vs 6.5±0.6%, n=23, P<0.01, control: 7.3±0.4 vs 6.5±0.7%, n=24, P<0.01), although they were similar at 6 months in the two groups. Only three hypoglycemic episodes were recorded among 50 subjects. We found no efficacy of glimepiride titration protocol in this study. However, glimepiride significantly improved glycemic control in fairly controlled diabetic patients without severe hypoglycemia.

show abstract

Section: Discussionsupporting

confidence: 79%

Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes

Kanazawa¹,

Shimizu²,

Ebato³

et al. 2009

TODIAJ

View full text Add to dashboard Cite

show abstract

“…17 Given the annual rates of drift and the initial HbA 1c treatment effects estimated in the NMA, it is apparent that the annual rates of drift are likely to be as, if not more, important than the HbA 1c treatment effects estimated in the NMA. Owing to the NMA estimating HbA 1c from 24-week data, half the annual drift is added to the estimated treatment effect to provide the 52-week estimate.…”

Section: Glycated Haemoglobin Evolutionmentioning

confidence: 99%

“…There is some evidence that the duration of effectiveness is longer with gliclazide than glibenclamide. 17 The main AEs of the SUs are weight gain and hypoglycaemia. A population-based study from Tayside found an incidence of severe hypoglycaemia amongst people on SUs of 0.9 per 100 patient-years.…”

Section: Sulfonylureasmentioning

confidence: 99%

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Johnston

Uthman

Cummins

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate metformin, which causes diarrhoea in about 10%, and it cannot be used in people with renal impairment. This review appraises three of the newest class of drugs for monotherapy when metformin cannot be used, the sodium–glucose co-transporter 2 (SGLT2) inhibitors. Objective To review the clinical effectiveness and cost-effectiveness of dapagliflozin (Farxiga, Bristol-Myers Squibb, Luton, UK), canagliflozin (Invokana, Janssen, High Wycombe, UK) and empagliflozin (Jardiance, Boehringer Ingelheim, Ingelheim, Germany/Eli Lilly and Company, Indianapolis, IN, USA), in monotherapy in people who cannot take metformin. Sources MEDLINE (1946 to February 2015) and EMBASE (1974 to February 2015) for randomised controlled trials lasting 24 weeks or more. For adverse events, a wider range of studies was used. Three manufacturers provided submissions. Methods Systematic review and economic evaluation. A network meta-analysis was carried out involving the three SGLT2 inhibitors and key comparators. Critical appraisal of submissions from three manufacturers. Results We included three trials of dapagliflozin and two each for canagliflozin and empagliflozin. The trials were of good quality. The canagliflozin and dapagliflozin trials compared them with placebo, but the two empagliflozin trials included active comparators. All three drugs were shown to be effective in improving glycaemic control, promoting weight loss and lowering blood pressure (BP). Limitations There were no head-to-head trials of the different flozins, and no long-term data on cardiovascular outcomes in this group of patients. Most trials were against placebo. The trials were done in patient groups that were not always comparable, for example in baseline glycated haemoglobin or body mass index. Data on elderly patients were lacking. Conclusions Dapagliflozin, canagliflozin and empagliflozin are effective in improving glycaemic control, with added benefits of some reductions in BP and weight. Adverse effects are urinary and genital tract infections in a small proportion of users. In monotherapy, the three drugs do not appear cost-effective compared with gliclazide or pioglitazone, but may be competitive against sitagliptin (Januvia, Merck Sharp & Dohme Limited, Kenilworth, NJ, USA). Funding The National Institute for Health Research Health Technology Assessment programme.

show abstract

“…The incidence of so‐called secondary failure has been reported to differ among SU drugs25. Both Harrower25 and Satoh et al 26. reported that the incidence of secondary failure was higher for glibenclamide than gliclazide.…”

Section: Discussionmentioning

confidence: 99%

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

Kubota

Yabe

Kanamori³

et al. 2014

J of Diabetes Invest

View full text Add to dashboard Cite

We analyzed the changes of glycemic control over 12 months and the factors influencing blood glucose in 162 Japanese patients with type 2 diabetes having inadequate glycemic control despite sulfonylurea‐based therapy who received add‐on sitagliptin. Hemoglobin A1c (HbA1c) decreased significantly after 4 weeks of treatment, and this improvement was maintained for 1 year, although HbA1c was slightly higher in week 52 than in week 24. Comparison of the patients showing a ≥0.4% increase of HbA1c between weeks 24 and 52 (n = 57) with the others (n = 105) showed a significant difference in the change of bodyweight, as well as the dose of glibenclamide (both P < 0.01). Although combined therapy with sitagliptin and a sulfonylurea seems to be effective for at least 1 year, blood glucose levels are more likely to increase again in patients who show greater weight gain after 24 weeks of treatment and those receiving a higher dose of glibenclamide.

show abstract

Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide

Cited by 44 publications

References 22 publications

Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes

Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

Contact Info

Product

Resources

About